Skip to main content
Evidence Snapshot

Myeloperoxidase

CHEMBL2439 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T11:40:54Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2439
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Myeloperoxidase as ChEMBL target CHEMBL2439, mapped to UniProt P05164. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Myeloperoxidase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2439
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P05164
Myeloperoxidase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Myeloperoxidase matters

As of 2026-09-13

Myeloperoxidase is reviewed as Myeloperoxidase (UniProt P05164); Myeloperoxidase shows late clinical disease relevance led by multiple system atrophy. 3 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 10 approved drugs, 867 compounds, and 168 assays, with lead potency reaching pChEMBL 9.0.

Disease context
multiple system atrophy

Myeloperoxidase shows late clinical disease relevance led by multiple system atrophy. 3 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 3 additional disease programs remain visible in the same card. Linked drugs include VERDIPERSTAT.

Start review with multiple system atrophy because it currently carries late clinical support. Linked drugs include VERDIPERSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Late clinical 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 10 approved drugs, 867 compounds, and 168 assays for this target. The dominant activity type is IC50. CHEMBL4747269 is the current potency anchor at pChEMBL 9.0.

Use CHEMBL4747269 as the tractability anchor when discussing potency (pChEMBL 9.0).

Activity source · ChEMBL 36 via Core Engine
10 approved pChEMBL 9.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Myeloperoxidase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P05164, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why multiple system atrophy is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

867
Total Compounds
168
Total Assays
10
Approved Drugs
IC50: 1093.0, KI: 6.0, EC50: 23.0, KD: 6.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4747269
 9.0 IC50 —
No preferred name
CHEMBL4790231
 9.0 IC50 —
No preferred name
CHEMBL5639106
 9.0 IC50 —
No preferred name
CHEMBL5197968
 8.9 IC50 —
No preferred name
CHEMBL5095218
 8.8 IC50 Clinical

Approved Drugs

Structure Compound First Approval
PAROXETINE
CHEMBL490
 1992
METOCLOPRAMIDE
CHEMBL86
 1979
DAPSONE
CHEMBL1043
 1979
MEFENAMIC ACID
CHEMBL686
 1967
HYDRALAZINE
CHEMBL276832
 1953
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T11:40:54Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2439